Bachem Holding AG
BANB
Kedudukan dalam Saham
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Harga Saham
$100.60
Modal Pasaran
$7.54B
Perubahan (1 hari)
-1.49%
Perubahan (1 tahun)
49.53%
Negara
CH
Perdagangan Bachem Holding AG (BANB)
Kategori
Healthcare
Nisbah P/E bagi Bachem Holding AG (BANB)
Nisbah P/E pada October 2026 TTM: 41.76
Menurut laporan kewangan dan harga saham terkini Bachem Holding AG, nisbah P/E semasa (TTM) ialah 41.76. Pada akhir 2024, syarikat mempunyai nisbah P/E sebanyak 36.10.
Sejarah nisbah P/E bagi Bachem Holding AG dari 2002 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 41.76 | 38.05% |
| 2025 | 30.25 | -16.21% |
| 2024 | 36.10 | -16.81% |
| 2023 | 43.40 | -25.78% |
| 2022 | 58.48 | -33.90% |
| 2021 | 88.46 | 24.74% |
| 2020 | 70.92 | 79.34% |
| 2019 | 39.54 | 18.49% |
| 2018 | 33.37 | -33.30% |
| 2017 | 50.04 | 68.55% |
| 2016 | 29.69 | 34.57% |
| 2015 | 22.06 | -3.17% |
| 2014 | 22.78 | -17.87% |
| 2013 | 27.74 | -13.45% |
| 2012 | 32.05 | -31.13% |
| 2011 | 46.54 | 74.64% |
| 2010 | 26.65 | 37.59% |
| 2009 | 19.37 | 5.36% |
| 2008 | 18.38 | -7.54% |
| 2007 | 19.88 | -23.58% |
| 2006 | 26.01 | -79.50% |
| 2005 | 126.87 | 374.25% |
| 2004 | 26.75 | 2,864.92% |
| 2003 | 0.90 | 10,771.08% |
| 2002 | 0.01 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 28.78 | -31.08% |
US
|
|
| -28.36 | -167.91% |
US
|
|
| -25.99 | -162.24% |
AU
|
|
| 31.22 | -25.24% |
NL
|
|
| - | - |
CH
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.